These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23232055)

  • 21. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
    Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
    Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
    Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
    Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-delivery of Siape1 and Melatonin by
    Liu Y; Hao L; Dong Y; Dong BZ; Wang XL; Liu X; Hu ZX; Fang GC; Wang GY; Qin JX; Shi ZD; Pang K
    Recent Pat Anticancer Drug Discov; 2024; 19(4):503-515. PubMed ID: 39044710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
    Aggarwal S; Singh P; Topaloglu O; Isaacs JT; Denmeade SR
    Cancer Res; 2006 Sep; 66(18):9171-7. PubMed ID: 16982760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
    Liu T; Wu LY; Kazak M; Berkman CE
    Prostate; 2008 Jun; 68(9):955-64. PubMed ID: 18361407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
    Patil Y; Shmeeda H; Amitay Y; Ohana P; Kumar S; Gabizon A
    Nanomedicine; 2018 Jun; 14(4):1407-1416. PubMed ID: 29680672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA).
    Chandran SS; Banerjee SR; Mease RC; Pomper MG; Denmeade SR
    Cancer Biol Ther; 2008 Jun; 7(6):974-82. PubMed ID: 18698158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of
    Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
    J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
    Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
    Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
    Matthias J; Engelhardt J; Schäfer M; Bauder-Wüst U; Meyer PT; Haberkorn U; Eder M; Kopka K; Hell SW; Eder AC
    Cancer Res; 2021 Apr; 81(8):2234-2245. PubMed ID: 33622696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
    Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
    Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
    Hillier SM; Kern AM; Maresca KP; Marquis JC; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2011 Jul; 52(7):1087-93. PubMed ID: 21680691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.